#China #Shanghai #Medical Aesthetics #Aphranel #Lin Guangming

The Future of Medical Aesthetics in China: Insights from Aphranel's Founder

In a significant move for the medical aesthetics landscape in China, Lin Guangming, the founder of Moyom Biotechnology and its Aphranel brand, was recently invited by People's Daily to join a crucial industry discussion. This dialogue took place during the annual legislative meetings, commonly referred to as the "Two Sessions." It aimed to delve into the long-term development of the medical aesthetics sector, focusing on clinically-grounded approaches and robust regulatory practices.

A Platform for Change

The event, organized by the health platform of People's Daily, gathers key industry players along with academic experts to discuss pressing issues such as regulatory compliance, clinical standards, and the evolving nature of medical aesthetics within the wider healthcare system of China. People's Daily, being one of the most read official media outlets in the country, provided an ideal platform for such vital discussions.

On March 17, 2026, a special program featured Lin Guangming alongside Professor Shi Bin, who is the Chair of the Plastic and Aesthetic Committee of the Chinese Medical Institutions Association. Together, they addressed the importance of reinforcing medical aesthetics as an established clinical discipline governed by stringent standards and responsible treatment protocols.

Professor Shi pointed out that recognizing medical aesthetics as a legitimate medical field is crucial. He mentioned that recent policy enhancements in China would significantly strengthen the oversight of qualified practitioners, compliant products, accredited institutions, and standardized clinical practice.

Insights from a Decade of Research

Drawing from his extensive background, Lin shared insights from over a decade of research and development focused on calcium hydroxylapatite (CaHA) fillers. Aphranel's commitment to quality and safety is evident in their 11-year journey which included laboratory research, regulatory approvals, and clinical validations, positioning their products at the forefront of medical aesthetic innovation.

Lin elaborated on the unique characteristics of Aphranel's CaHA microspheres, which are specifically designed with particle sizes around 30–35 μm. These microspheres feature a raspberry-shaped surface and a through-hole structure that encourage cell adhesion and tissue integration. The material demonstrates a reported elastic modulus of approximately 5500 Pa, which ensures both structural support and injection stability.

What sets Aphranel apart is its commitment to biodegradable materials that avoid residual chemicals, while simultaneously promoting active collagen regeneration—a cornerstone of effective medical aesthetics.

A New Brand Philosophy

Lin introduced Aphranel's new philosophy, termed "Be With Time, Be Like Me," which emphasizes gradual and sustainable results while fostering long-term engagement with patients. This approach aligns perfectly with the current trend within the medical aesthetics field that prioritizes treatment quality and durability, reflecting a strong shift towards clinically validated outcomes.

Navigating Global Markets

Aphranel is not only focusing on the domestic market but has also made strides in global platforms, including major gatherings like IMCAS in Paris, renowned as a leading congress for medical aesthetics and dermatology. Here, the company championed its "Poetics of Time" concept, advocating for a paradigm shift from seeking instant results to emphasizing lasting effects of treatments.

Progressively, Aphranel is expanding its international footprint. After securing domestic regulatory approvals, the brand is advancing through the EU MDR evaluation, strategically positioning itself for entry into some of the most highly regulated markets in the world.

Premium Positioning in the Aesthetics Market

As per company reports, Aphranel’s products are designed for use within certified medical institutions. Positioned in the premium segment of regenerative CaHA fillers, they cater to the higher price tier in the aesthetics market while emphasizing advanced material science and a commitment to long-term clinical success.

These recent developments underscore a pivotal moment in China’s medical aesthetics industry, as it embarks on a path towards greater regulation and clinical standardization, setting higher benchmarks for practice.

The participation of leaders like Lin Guangming signifies a promising shift in the medical aesthetics sector, aiming to blend innovation and safety for optimal patient outcomes.